This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q4 Earnings Season Scorecard and Research Reports for Toyota, PepsiCo & BlackRock
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.
Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod
by Zacks Equity Research
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised
by Zacks Equity Research
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright
by Zacks Equity Research
AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.
Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 13.39% and 0.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat
by Zacks Equity Research
Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.
Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT
by Zacks Equity Research
Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.
Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings
by Zacks Equity Research
Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.
Microsoft (MSFT) Q2 Earnings Beat, Azure & Gaming Aid Top Line
by Zacks Equity Research
Microsoft's (MSFT) fiscal second-quarter results benefit from momentum in Azure, impressive Teams user growth led by work-from-home wave and solid uptake of new Xbox consoles.
Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.
Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
Top Stock Reports for NIKE, Amgen & Morgan Stanley
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
Why Amgen (AMGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
by Zacks Equity Research
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Stock Market News for Jan 11, 2021
by Zacks Equity Research
Benchmarks hit fresh record highs on Friday as President-elect Joe Biden promised new fiscal aid following a weak December jobs data.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
by Zacks Equity Research
Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.